- Home
- RCUS vs ATLC Comparison
RCUS vs ATLC Comparison
Compare RCUS & ATLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCUS
- ATLC
- Stock Information
- Founded
- RCUS 2015
- ATLC 1996
- Country
- RCUS United States
- ATLC United States
- Employees
- RCUS N/A
- ATLC N/A
- Industry
- RCUS Biotechnology: Pharmaceutical Preparations
- ATLC Finance: Consumer Services
- Sector
- RCUS Health Care
- ATLC Finance
- Exchange
- RCUS Nasdaq
- ATLC Nasdaq
- Market Cap
- RCUS 906.4M
- ATLC 900.3M
- IPO Year
- RCUS 2018
- ATLC 1999
- Fundamental
- Price
- RCUS $10.40
- ATLC $61.35
- Analyst Decision
- RCUS Buy
- ATLC Buy
- Analyst Count
- RCUS 8
- ATLC 7
- Target Price
- RCUS $20.71
- ATLC $66.14
- AVG Volume (30 Days)
- RCUS 783.0K
- ATLC 44.4K
- Earning Date
- RCUS 08-06-2025
- ATLC 08-07-2025
- Dividend Yield
- RCUS N/A
- ATLC N/A
- EPS Growth
- RCUS N/A
- ATLC 35.13
- EPS
- RCUS N/A
- ATLC 5.69
- Revenue
- RCUS $262,000,000.00
- ATLC $457,158,000.00
- Revenue This Year
- RCUS N/A
- ATLC $274.30
- Revenue Next Year
- RCUS $28.73
- ATLC $12.69
- P/E Ratio
- RCUS N/A
- ATLC $10.92
- Revenue Growth
- RCUS 6.07
- ATLC 26.20
- 52 Week Low
- RCUS $6.50
- ATLC $30.00
- 52 Week High
- RCUS $18.98
- ATLC $64.70
- Technical
- Relative Strength Index (RSI)
- RCUS 63.56
- ATLC 70.20
- Support Level
- RCUS $9.73
- ATLC $49.05
- Resistance Level
- RCUS $10.23
- ATLC $62.86
- Average True Range (ATR)
- RCUS 0.53
- ATLC 2.28
- MACD
- RCUS 0.07
- ATLC 1.44
- Stochastic Oscillator
- RCUS 82.11
- ATLC 89.07
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
About ATLC Atlanticus Holdings Corporation
Atlanticus Holdings Corp invests in the financial services industry. It provides various credit and related financial services and products to or associated with the financially underserved consumer credit market. The operating business segments are the Credit as a Service (CaaS) and the Auto Finance segment. It generates maximum revenue from the Credit as a Service segment.